Find a Cancer Expert
The Winship Cancer Institute has leading cancer experts in both clinical and research arenas available to speak at your event or as a topical authority. Listed below is a small sample of the experts available as keynote speakers, presenters or to provide expert commentary . For more information, please contact:
1365 Clifton Road, Bldg. C
Atlanta, GA 30322
Aerodigestive Cancers: Lung cancer, head and neck cancer, throat cancer
Leukemia, Lymphoma Multiple Myeloma
Aerodigestive Cancers: Lung cancer, head and neck cancer, throat cancer. Also: Drug Discovery.
Fadlo Khuri, MD, Deputy Director for Clinical and Translational Research, Winship Cancer Institute of Emory University and Chairman of the Department of Hematology and Medical Oncology. Dr. Khuri’s clinical interests include thoracic and head and neck oncology. His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in tobacco-related cancers. He is the recipient of a Georgia Cancer Coalition Distinguished Clinical Scholar Award, serves on the editorial boards of seven journals, including the Journal of Clinical Oncology, Clinical Cancer Research and Cancer, and has published over 140 peer reviewed articles in elite journals including Nature Medicine, Journal of the National Cancer Institute, Cancer Research, and the Journal of Clinical Oncology. He has been the recipient of continuous, competitive, peer-reviewed federal grant support from the National Cancer Institute, Department of Defense, and American Cancer Society.
Dong M. Shin, MD, FACP, Professor of Hematology, Oncology, and Otolaryngology, Winship Cancer Institute of Emory University. Dr. Shin’s clinical and research focus is in head, neck and lung cancers. His research has been in developing biomarkers in animal and human carcinogenesis for head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor receptor (EGFR) signaling pathways; and developing novel therapeutics for head and neck cancer, lung cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer patients using nanotechnology.
Amy Chen, MD, MPH Assistant Professor in the Department of Otolaryngology and Head and Neck Surgery and in the Department of Hematology and Medical Oncology at The Emory University School of Medicine. Her expertise is in upper aerodigestive tract cancers, parotid, and thyroid tumors. She also serves as Program Director for Head and Neck Clinical Research and Intervention at the Winship Cancer Institute of Emory University and has a joint appointment at Emory’s Rollins School of Public Health. She also is a Physician-Scientist in the Epidemiology/ Surveillance Section of the American Cancer Society. Dr. Chen’s major focus of research is directed toward measuring outcomes of oncology treatment as well as measuring determinants of successful outcomes of care.
Suresh Ramalingam, MD Director of the translational thoracic malignancies program, and acting assistant professor of hematology and oncology at Winship Cancer Institute of Emory University. Dr. Ramalingam comes to Emory from the University of Pittsburgh School of Medicine. He specializes in lung cancer, esophageal cancer and other thoracic cancers and is actively involved in the scientific development of novel anti-cancer treatment agents. Dr. Ramalingam serves as the principal investigator on several early phase clinical trials in lung cancers, many of which are sponsored by the NCI. He is widely published in peer-reviewed scientific journals and serves as a reviewer for a number of medical journals.
Return to top of list.
Rebecca Pentz, PhD, Professor of Hematology & Medical Oncology in Research Ethics. Rebecca Pentz, PhD, joined the Winship Cancer Institute of Emory University from the University of Texas M.D. Anderson Cancer Center in Houston, where she was associate professor of Clinical Ethics. She received her Doctorate in Philosophy from the University of California at Irvine. Dr. Pentz is a widely published investigator and author in bioethics. Her research focuses on ethical issues involved in oncology research, genetic testing, clinical trial development, informed consent and privacy. Dr. Pentz also sits on various national research committees, among them: the Central Institutional Review Board sponsored by the National Cancer Institute; the Children’s Oncology Group Ethics Committee; the Cancer Genetics Network—Ethics Working Group; and the Centers for Disease Control Institutional Review Board.
Return to top of list.
William Wood, MD Appointed Joseph Brown Whitehead Professor and Chairman of the Department of Surgery, Emory University School of Medicine in 1991, Dr. William Wood is globally recognized for his outstanding contributions to cancer therapy and his influence on the design and meta-analysis of conceptually driven national clinical trials. A medical graduate of Harvard Medical School in 1966, Dr. Wood was a clinical and research fellow in immunology at the surgery branch of the NIH from 1968-1970. Subsequently, he completed a clinical fellowship in surgery at Harvard in 1973 and his general surgery residency at Massachusetts General Hospital in 1974. Before coming to Emory, Dr. Wood served as both Medical Director of the Cancer Center and Chief of Surgical Oncology at Massachusetts General Hospital.
Ruth O’Regan, MD Associate Professor, Hematology and Medical Oncology. Dr. O’Regan is Associate Professor, Hematology and Medical Oncology at the Winship Cancer Institute of Emory University and Director of Winship’s Translational Breast Cancer Research Program. She was recently named to the Louisa and Rand Glenn Family Chair in Breast Cancer Research. Dr. O’Regan is widely published in peer reviewed scientific journals, having published articles in journals such as Lancet Oncology, the Journal of the National Cancer Institute and the Journal of the American Medical Association. Dr. O’Regan’s laboratory focuses on the use of nanoparticles conjugated to antibodies to detect and quantify proteins important in breast cancer as well as the mechanisms of selective estrogen receptor modulator (SERM) resistance. Dr. O’Regan is a current member of the breast cancer scientific committee of the American Society of Clinical Oncology.
Amelia Zelnak, MD Assistant Professor of Hematology and Medical Oncology at Winship Cancer Institute of Emory University. She is Board Certified in Internal Medicine and earned her medical degree at Emory University. Dr. Zelnak completed a Fellowship in Hematology and Oncology at Emory’s Winship Cancer Institute. Her areas of research interest include ER-, PR-, Her2neu- (Triple Negative) breast cancers which are seen with increased frequency in young African American women. She is the principal investigator of a phase II clinical trial of gemcitabine and oxaliplatin for treatment of triple negative metastatic breast cancer. She is also currently developing a phase II clinical trial for preoperative treatment of triple negative breast cancers incorporating the anti-angiogenic drug sorafenib.
Return to top of list.
Leukemia, Lymphoma, Multiple Myeloma
Edmund Waller, MD, FACP, Professor of Hematology and Medical Oncology, Medicine, and Pathology at Emory School of Medicine. Dr. Waller serves as the Director of the Bone Marrow and Stem Cell Transplant Center at Emory. His research focus is enhancing immune reconstitution after stem cell transplant and anti-tumor immunology. He has research support from the National Institutes of Health, The Leukemia & Lymphoma Society, and National Marrow Donor Program. He also serves as Medical Director of Clinical Trials at Winship Cancer Institute of Emory University. He previously served on the Board of Directors for The Leukemia & Lymphoma Society's Georgia Chapter.
H. Jean Khoury, MD, Professor of Hematology and Oncology Associate Professor of Hematology and Oncology, Section Chief of Hematology. Dr. Khoury, a native of Beirut, Lebanon, comes to the Winship Cancer Institute of Emory University from Washington University School of Medicine, in St. Louis, Missouri. He earned his medical degree from the Universite Catholique de Louvain in Brussels, Belgium, completed his residency in Internal Medicine at Memorial Medical Center in Savannah, Georgia, and his fellowship in Hematology and Medical Oncology at Washington University. Dr. Khoury has a special interest in leukemia and myelodysplasia . He is currently implementing a program of genetic profiling of cancer cells in patients with hematological cancers. This data will be used to help determine the prognosis of clinical outcomes, and help physicians decide if a bone marrow transplant is necessary to prevent relapse following standard chemotherapy.
Sagar Lonial, MD, Professor and Director of Translational Research, B-cell malignancy program, Winship Cancer Institute of Emory University. Dr. Lonial has focused on combinations of novel agents as therapy for multiple myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the National Cancer Institute, Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society.
Return to top of list.
Shuming Nie, PhD, Professor, Emory University and Georgia Institute of Technology and Director, Cancer Nanotechnology Programs, Winship Cancer Institute of Emory University. Shuming Nie is one of the world's leaders in detecting single molecules in biological systems -- the science of nanotechnology. He is one of the first scientists in the world to utilize nanotechnology, which has been used in manufacturing for many years, in the biomedical field. Dr. Nie’s research is in the areas of biomolecular engineering and nanotechnology, with a focus on bioconjugated nanoparticles for cancer molecular imaging, molecular profiling, pharmacogenomics, and targeted therapy.
Return to top of list.